This Terns Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Barclays analyst Etzer Darout downgraded Terns Pharmaceuticals, Inc. (NASDAQ: TERN) from Overweight to Equal-Weight, reducing the price target from $56 to $53. Terns Pharma shares closed at $52.92 on Friday. This downgrade is part of a broader trend, as several companies faced similar rating changes from various analysts.